Biomarker Consortium

Biomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhD

May 8th 2026

Michael J. Pishvaian, MD, PhD discusses how biomarker-directed strategies, including HER2, CLDN18.2, and KRAS inhibition, are transforming GI cancer care.

John Marshall, MD, chief, Hematology and Oncology, professor, medicine and oncology, director, Otto J Ruesch Center for the Cure of Gastrointestinal Cancers, Georgetown Lombardi Comprehensive Cancer Center; Christopher Lieu, MD, professor, medicine, associate director, Clinical Research, co-director, Gastrointestinal Medical Oncology, University of Colorado Anschutz and the University of Colorado Cancer Center

New Trials and Targeted Approaches Advance the Precision of GI Cancer Care: With John Marshall, MD; and Christopher Lieu, MD

ByJohn L. Marshall, MD,Christopher Lieu, MD

March 27th 2026

Drs Marshall and Lieu discuss the clinical relevance of KRAS G12C and pan-RAS inhibitors in the management of pancreatic and colorectal cancers.

Scott Kopetz, MD, PhD, FACP, deputy chair, Translational Research, professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, leader, Department of Cancer Center Support Grant, GI Program, TRACTION medical director, Division of Therapeutics Discovery, associate vice president, Translational Integration, The University of Texas MD Anderson Cancer Center

Advances in ctDNA Testing Guide Clinical Decision-Making in GI Cancer Management: With Scott Kopetz, MD, PhD, FACP

ByScott Kopetz, MD, PhD, FACP

September 3rd 2025

Dr Kopetz discusses the value of ctDNA assays, trials that have shown prognostic implications with this type of assay, and the future of ctDNA research.

Martin F. Dietrich, MD, PhD, medical oncologist, Cancer Care Centers of Brevard; assistant professor, internal medicine, University of Central Florida

Guideline Updates and Trial Data Solidify the Role of HER2/MET IHC Testing in NSCLC: With Martin F. Dietrich, MD, PhD

ByMartin Dietrich, MD, PhD

August 4th 2025

Dr Dietrich discusses the rationale for testing for HER2 and MET mutations in patients with NSCLC, as well as best practices for implementing this testing.

Biomarker Consortium

Biomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhD

New Trials and Targeted Approaches Advance the Precision of GI Cancer Care: With John Marshall, MD; and Christopher Lieu, MD

Advances in ctDNA Testing Guide Clinical Decision-Making in GI Cancer Management: With Scott Kopetz, MD, PhD, FACP

Guideline Updates and Trial Data Solidify the Role of HER2/MET IHC Testing in NSCLC: With Martin F. Dietrich, MD, PhD

Trending on OncLive

Targeted Therapies, ADCs, and Oral SERD Combos Expand Treatment Possibilities Across Breast Cancer Settings

Head and Neck Oncologists Highlight Practice-Informing Research From ASCO 2026

Dr Galsky on the Current Roles of Biomarkers in Bladder Cancer

Sonrotoclax Plus Zanubrutinib Yields High Undetectable MRD Rates in Treatment-Naive CLL/SLL

FDA Grants Priority Review to Adjuvant Atezolizumab Plus Chemotherapy for Stage III dMMR Colon Cancer